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OBJECTIVES: To analyse the cost-effectiveness of adding adju-
vant postoperative radiotherapy (RT) to medical therapy after
breast conservation surgery in Stages I–II breast cancer in
Sweden. METHODS: A stochastic decision analytic model
follows patients from primary breast conservation therapy
during adjuvant therapy and includes ﬁve possible events of local
or regional events, metastases and death. Clinical data were
taken from a randomised clinical trial (SweBCG 91-RT) includ-
ing 1187 women aged 75 or younger who had received breast
conservation surgery and axillary dissection in Sweden between
1991 and 1997 and with a median follow-up of ﬁve years. Data
on health care costs were taken from a breast cancer register, a
health care database including all hospital and primary care con-
tacts in the West Health care Region. Costs for pharmaceuticals,
hospice, homecare and values of utilities were taken from the lit-
erature. RESULTS: Model results show a ten years risk of local
and regional event of 24.1 and 8.4 percent for the no RT and
RT groups, respectively. There was a signiﬁcant increase in
average Quality Adjusted Life Years (QALYs) of 0.13 (from 7.60
to 7.73) but no signiﬁcant difference in average life expectancy.
Treatment costs increased from SEK97,467 (€10,800) to
SEK101,453 (€11,300) per patient. RT shows an incremental
cost per QALY of SEK 32,000 (€3600). Model applications for
15 and 20 years results in cost savings due to a larger amount
of prevented relapses. Considering RT as an add-on to novel
adjuvant medical treatments regimens will however, reduce the
incremental beneﬁt of radiotherapy and the subsequent cost
offsets. CONCLUSIONS: Postoperative RT is cost-effective for
pre- and postmenopausal breast cancer women with Stage I–II
undergoing breast conservation therapy in Sweden only as an
adjunction to no medical adjuvant treatment. As an adjunct to
novel adjuvant medical therapies, RT is cost-effective in high-
risk groups.
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OBJECTIVES: In 2005, bortezomib received regulatory
approval in Canada for the treatment of multiple myeloma
(MM) patients who have relapsed following front-line therapy
and are refractory to their most recent therapy. Prior to this
approval, treatment options for this patient group were very
limited and included best supportive care (BSC). The objective
was to conduct an economic analysis of bortezomib versus BSC
in relapsed and refractory MM patients. METHODS: The clin-
ical evidence (survival and QOL) for the analysis was taken from
the SUMMIT trial (NEJM 2003;384:2609–2617), a Phase II trial
of bortezomib in 202 relapsed and refractory MM patients.
These patients were heavily pre-treated with a median of six
prior lines of therapy. In order to properly represent such a
refractory group of patients, the Progressive Disease subgroup of
patients in SUMMIT were used to estimate how a BSC group
would perform. Utility score was indirectly obtained from
mapping patient QOL (EORTC-QLQC30, MY24, FACIT-
Fatigue, FACT/GOG-Ntx) onto dimensions in ED-5D. Resource
use from SUMMIT was used to estimate costs from the Ontario
Ministry of Health perspective. RESULTS: Bortezomib produced
a survival gain of 9.95 months (range 7.75 to 12.09 months), 
a QALY gain of 0.53 QALY, and an incremental cost of
CAN$37,662 per patient. The incremental cost-effectiveness
ratio (ICER) was CAN$45,399 (range $37,380 to $58,288) per
LY and incremental cost-utility ratio (ICUR) was CAN$70,852
(range $58,189 to $89,791) per QALY. Sensitivity analyses did
not produce wide changes in the ICER or ICUR. CONCLU-
SIONS: Bortezomib is a cost-effective option for this patient pop-
ulation that has limited available therapies.
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OBJECTIVES: A drug protocol that incorporated docetaxel with
the conventional anticancer agents doxorubicin and cyclophos-
phamide (TAC) has shown better efﬁcacy than 5-FU with the
same agents (FAC) in terms of disease-free survival and overall
survival, in a long term (5 year) randomised controlled trial in
women with early breast cancer (BCIRG001 trial). Considering
the cost difference between the two regimens and the potentially
large number of patients affected by this new indication, an eco-
nomic assessment was deemed necessary. METHODS: In order
to assess long term costs and effectiveness of both regimens
beyond the time scope of the trial, we developed a lifetime
Markov model comparing TAC and FAC. Four health states
were deﬁned: alive without relapse, alive with loco-regional
relapse, alive with distant relapse and dead. Transitions occurred
every 6 months accordingly to time dependent transition proba-
bilities derived from the clinical trial. Model consistency was
checked against the 5-year trial results. We took into account
costs of initial chemotherapy, of severe (grade 3/4) adverse events
(febrile neutropenia, stomatitis, diarrhoea, infection), of sec-
ondary prophylaxis with growth factors and of follow-up after
treatment. In case of relapse, a cost was assigned to patients
including pre-treatment check-up, chemotherapy, supportive
care and follow-up. The perspective was that of the French
public health insurance. RESULTS: Patients receiving TAC had
a longer life expectancy than those treated with FAC (28.61
versus 26.33 years). Overall lifetime average costs were €20,837
and €16,143 respectively for TAC and FAC. The incremental
